India Expected To Get Next Set Of U.S. FDA Permanent Staff
This article was originally published in PharmAsia News
India is likely to be next on the list of U.S. FDA plans to station inspectors in other countries as a follow-up to a similar step earlier in March in China. The agency said it would have eight full-time positions in China to monitor medicines intended for export to the United States, and plans to locate personnel in Europe, India, South America and West Asia. India is expected to be next to receive U.S. FDA inspectors since it has the largest number of FDA-approved drug plants outside the United States. (Click here for more
You may also be interested in...
Phase I data presented at ASCO for ALLO-501 offer proof of concept for the CD19 allogeneic CAR-T and a companion drug, ALLO-647, for lymphodepletion.
Dispatches from a world turned upside down covering a possible US government investigation into BARDA contracting practices and Medicare Part D plans waiving cost sharing for COVID-19 treatments.
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.